Install
The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more. The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval. Serota and other field experts discussed best practices as well as new t
- 10articles · 30d
- 4+ day agolatest article
- Aug 18, 2026earliest in window
- 100%with images
- 221avg words
- Medical 10
- Health 9
- Health & Wellness 7
- Beauty & Fitness 3
- Education 1
- dermatology
- skin health
- 83rd american academy
- integument 2 phase 3 trials
- atopic dermatitis
- prior inadequate response
- patient reported outcomes
- including intertriginous areas
- pediatric patients 6 years
- moderate atopic dermatitis
- pediatric patients 9 years
- severe liver impairment
- common adverse reactions
- plaque psoriasis include diarrhea
- application site pain
- upper respiratory tract infection
- urinary tract infection
- tmt newswire
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Biologic Therapy Linked to Lower 10-Year MACE Risk Across Racial Groups in Psoriasis
6+ day, 20+ hour ago (350+ words) Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races. The study used de-identified data from the TriNetX research platform collected between 2015 and 2025. Investigators identified adults aged 18 to…...